V.R. Archer

Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704

C. Manegold, Joachim von Pawel, Petr Zatloukal et al. · Journal of Clinical Oncology · 2007 · 167 citations

Medicine, Oncology, Pharmacology +11

Pr4 ISEL: A Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens

Nicholas Thatcher, Amy Chang, Purvish Parikh et al. · Lung Cancer · 2005 · 69 citations

Medicine, Oncology, Pharmacotherapy +11

Preoperative Mitomycin, Ifosfamide, and Cisplatin Followed by Esophagectomy in Squamous Cell Carcinoma of the Esophagus: Pathologic Complete Response Induced by Chemotherapy Leads to Long-Term Survival

S. Jane Darnton, V.R. Archer, Deborah Stocken et al. · Journal of Clinical Oncology · 2003 · 51 citations

Medicine, Oncology, Surgery +15

Palliative Chemotherapy: No Longer a Contradiction in Terms

V.R. Archer, Lucinda Billingham, M.H. Cullen · The Oncologist · 1999 · 51 citations · Full text

Medicine, Oncology, Chemotherapy +13

Final safety results of BO17704 (AVAiL): A phase III randomized study of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC)

Vera Hirsh, Rodryg Ramlau, Joachim von Pawel et al. · Journal of Clinical Oncology · 2009 · 28 citations

Medicine, Oncology, Pharmacology +13